Navigation Links
Ontario minister seconds patient-pay plan for expensive cancer drugs

The idea of permitting hospitals to effect a charge on cancer patients for powerful, intravenous medications, not sponsored by the public health-care //system, is being seriously considered by Ontario's Health Minister.

George Smitherman said "There's no final decision yet. We've done some due diligence and obviously we're closer to having a policy. And in my heart, I believe it's the right thing said in a telephone interview yesterday. I have a responsibility to consider this once I have seen the final advice and to make sure that it's the right thing at the right time for Ontario."

The patients would be allowed to pay for those cancer drugs that have the approval of Health Canada but are frightfully expensive, which may be needed to extend the life of patients suffering from incurable cancers. The proposal will permit thousands of Ontario patients to buy the IV drugs at half the price in comparison to the United States Market.

According to Carolyn Henry, group leader of the London and District Myeloma Support Group, said "Imagine delaying treatment for lack of money, having to fundraise for treatment, putting your kids' postsecondary education at risk, potentially having to sell your house because you can't keep up the mortgage payments, which you incurred to pay for treatment, because you can't work.”

Bill Evans, an oncologist and president of the Juravinski Cancer Centre in Hamilton, stating that many new cancer drugs are awfully expensive said "People are going to seek these things out and they are willing to pay for them. What are you going to do -- say no, and inconvenience people? Or try to help with the safety and continuity of their care by making them available?"


'"/>




Page: 1

Related medicine news :

1. Nurses In Ontario demands Safe Disposable Needles
2. Ontario Institute for Cancer Research is funded $142 million
3. Students wants to extent Tution waiver in Ontario
4. Patients In Ontario Wait Longer For Treatment
5. Ontario Unprepared To Deal With Flu Pandemic
6. Ontario’s Entire Drug System Undergoes a Revam
7. Chemotherapy Queues in Ontario Stay Steady
8. Ontario Ranks Highest in Free Bird Flu Vaccination Rates
9. Ontario Medical Association Planning To Lure Back Expat Doctors
10. Ontario Addresses Shortage of Transplant Organs
11. Ontario Continues Support for Autistic Children
Post Your Comments:
Other Medicine News:Health News:Express Scripts Announces Definitive Agreement to Acquire WellPoint NextRx Subsidiaries for $4.675 Billion 2Health News:Express Scripts Announces Definitive Agreement to Acquire WellPoint NextRx Subsidiaries for $4.675 Billion 3Health News:Express Scripts Announces Definitive Agreement to Acquire WellPoint NextRx Subsidiaries for $4.675 Billion 4Health News:Express Scripts Announces Definitive Agreement to Acquire WellPoint NextRx Subsidiaries for $4.675 Billion 5Health News:Express Scripts Announces Definitive Agreement to Acquire WellPoint NextRx Subsidiaries for $4.675 Billion 6Health News:Express Scripts Announces Definitive Agreement to Acquire WellPoint NextRx Subsidiaries for $4.675 Billion 7Health News:Express Scripts Announces Definitive Agreement to Acquire WellPoint NextRx Subsidiaries for $4.675 Billion 8Health News:Racial disparities persist in the treatment of lung cancer 2Health News:New alternative to biopsy detects subtle changes in cancer cells, Stanford study shows 2Health News:New alternative to biopsy detects subtle changes in cancer cells, Stanford study shows 3Health News:Stem Cells Spur New Eggs in Ovaries of Adult Mice 2Health News:Stem Cells Spur New Eggs in Ovaries of Adult Mice 3Health News:NEWSWEEK Cover: The Mystery of Epilepsy 2Health News:NEWSWEEK Cover: The Mystery of Epilepsy 3Health News:Arthritis Hand Pain Relief: Infrared Heat Therapy Ergonomic Computer Workstation 2
Breaking Medicine Technology:Hand Surgeons Take Ethics into Their Own Hands 2Hand Surgeons Take Ethics into Their Own Hands 3Hand Surgeons Take Ethics into Their Own Hands 4Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 2Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 4National Patient Safety Foundation Supports Mandatory Flu Vaccinations for Healthcare Workers 61647 1National Patient Safety Foundation Supports Mandatory Flu Vaccinations for Healthcare Workers 61647 2National Patient Safety Foundation Supports Mandatory Flu Vaccinations for Healthcare Workers 61647 3Reportlinker Adds Biotechnology Reagents A Global Market Perspective 14905 1Reportlinker Adds Biotechnology Reagents A Global Market Perspective 14905 2Reportlinker Adds Biotechnology Reagents A Global Market Perspective 14905 3Reportlinker Adds Biotechnology Reagents A Global Market Perspective 14905 4Reportlinker Adds Biotechnology Reagents A Global Market Perspective 14905 5Reportlinker Adds Biotechnology Reagents A Global Market Perspective 14905 6Reportlinker Adds Biotechnology Reagents A Global Market Perspective 14905 7Reportlinker Adds Biotechnology Reagents A Global Market Perspective 14905 8Improving Quality Cost Effectiveness and Time Savings in Preclinical Inhalable Formulation Development 6386 1Improving Quality Cost Effectiveness and Time Savings in Preclinical Inhalable Formulation Development 6386 2